Estradiol Drug Uses

Use Estrandiol to reduce moderate to severe menopausal symptoms, to treat vulval and vaginal atrophy, treat certain cancers in special situations and prevent the thinning of bones.

How Taken

Talk to your local physician or pharmacist. You and your doctor should reevaluate whether or not you still need estrogens at least every six months.

Estradiol Warnings/Precautions

If you think you may be pregnant, do not use any form of estrogen-containing drug. Using Estrandiol while you are pregnant may cause your unborn child to have birth defects. Estrandiol does not prevent miscarriage.

Estradiol Missed Dose

If you miss a dose, use it as soon as you remember. If it is near the time of the next dose, skip the missed dose and resume your usual dosing schedule. Do not double the dose to catch up.

Estradiol Possible Side Effects

The following side effects have been reported with use of this medicine: nausea and vomiting; breast tenderness or enlargement; enlargement of benign tumors; retention of excess fluid (this may make some conditions worsen, such as asthma, epilepsy, migraine, heart disease, or kidney disease); a spotty darken of the skin, particularly on the face.

Estradiol Storage

Store at controlled room temperature 15°C to 30°C (59°F to 86°F). Keep this and all drugs out of the reach of children.

Estradiol Overdose

In case of overdose, call your doctor, hospital or poison control center immediately.

More Information

You are cautioned to discuss very carefully with your doctor or health care provider all the possible risks and benefits of long-term estrogen and progestin treatment as they affect you personally.

Disclaimer

This drug information is for your information purposes only, it is not intended that this information covers all uses, directions, drug interactions, precautions, or adverse effects of your medication. This is only general information, and should not be relied on for any purpose. It should not be construed as containing specific instructions for any particular patient. We disclaim all responsibility for the accuracy and reliability of this information, and/or any consequences arising from the use of this information, including damage or adverse consequences to persons or property, however such damages or consequences arise. No warranty, either expressed or implied, is made in regards to this information.

More and more consumers are using Medspharmacy-online.com for health reasons. Over 3 billion prescriptions were dispensed in 2000.

* the privacy and convenience of ordering Estradiol from their homes

* greater availability of drugs for shut-in people or those who live far from the pharmacy

* the ease of comparative shopping among many sites to find the best prices

* greater convenience and variety of products

* easier access to written product information and references to other sources than in traditional storefront pharmacies


Q: Do you deliver Estradiol to my state?
A: Due to regulations we cannot ship medicines to all states, please check the order form for the current list of states that we can ship to.


Even as Evista (raloxifene) reduced the risk of invasive breast cancer by 44%, compared with placebo, it had a significantly increased relative risk of thromboembolic events -- including fatal strokes -- according to a study of more than 10,000 postmenopausal women. Evista was associated with a 49% increase in the relative risk of fatal stroke (P=0.05), Elizabeth Barrett-Connor, M.D., of the University of California San Diego and colleagues for the RUTH (Raloxifene Use for The Heart) trial reported in the July 13 issue of the New England Journal of Medicine. Evista was also associated with a significant increase in risks of venous thromoboembolic events (P=0.02), but as expected Evista was associated with a significant decrease in risk of clinical vertebral fractures (P=0.007). The 44% decrease in invasive breast cancer risk (P=0.003) among women taking Evista was driven by a highly significant reduction in estrogen-positive breast cancer (P<0.001). Evista did not reduce the risk of estrogen-negative breast cancers (P=0.40). Women taking Evista also had significantly more hot flushes, leg cramps, and peripheral edema (P<0.001 for all compared with placebo), they wrote. The RUTH investigators randomly assigned 10,101 postmenopausal women (mean age 67.5) with established coronary heart disease or multiple risk factors for heart disease to either 60 mg of Evista daily or placebo. The women were followed for a median of 5.6 years. The primary endpoints were coronary events and invasive breast cancer. In this group of women at high risk for coronary events, "the difference in absolute rates of events that were decreased (i.e., breast cancer and clinical vertebral fractures) was similar to the difference in the absolute rates of events that were increased (i.e., venous thromboembolic events and fatal strokes)," the authors wrote. And that may be the sticking point for many clinicians counseling women, said Steven Nissen, M.D., acting director of cardiology at the Cleveland Clinic. "When a drug increases cardiovascular risk, we have to take that seriously," he said adding that Dr. Barrett-Connor and colleagues did an excellent job of "laying out the risks and benefits very clearly, with no spin." Dr. Nissen, who was an early critic of Vioxx (rofecoxib) because of its increased risk of thromboembolic events, said that results of the RUTH trial are likely to spur debate if Lilly, the maker of Evista, seeks FDA approval for Evista for breast cancer prevention. Currently the drug is approved for treatment and prevention of osteoporosis in postmenopausal women. Earlier this year, results of the STAR (Study of Tamoxifen and Raloxifene) trial indicated that Evista is as effective as tamoxifen for preventing breast cancer in postmenopausal women. Tamoxifen is the only FDA approved drug for prevention of breast cancer. Lilly said in June that it plans to ask the FDA to approve Evista for cancer prevention. Evista and tamoxifen are both selective estrogen receptor modulators, or SERMs. SERMs were originally developed as alternatives to estrogen to treat symptoms of menopause as well as osteoporosis. But unlike estrogen, SERMs do not reduce vasomotor symptoms, although they have demonstrated efficacy in osteoporosis. When the RUTH trial began recruiting women in 1998 it was widely believed that estrogen reduced the risk of coronary events, which led Dr. Barrett-Connor and colleagues to hypothesize that Evista would also be cardio-protective. But in 2002, investigators for the Women's Health Initiative reported that estrogen increased the risk of stroke and thromboembolic events, as well as increasing the risk of breast cancer. The RUTH results "now allow us to say that all modulators of the estrogen receptors potentially increase the risk of cardiovascular events," said Dr. Nissen. John T. Cole, M.D., medical director of hematology and oncology services at the Ochsner Health System in New Orleans, said that the RUTH findings coming on the heels of the STAR trial confirm that Evista has a role in chemoprevention in a select population -- but defining that population may be difficult. Even so-called high risk women only have very small absolute risk for developing breast cancer, he said. "If you look at in terms of telling a woman that she has about a 98.4% chance of [not developing breast cancer], it is difficult to imagine her wanting chemoprevention," he said. Nonetheless, Dr. Cole said that in both the RUTH trial and the STAR trial "as risk increased, so did the potential benefit of chemoprevention." In an NEJM editorial, Marcia L. Stefanick, Ph.D., of the Stanford Prevention Research Center in Stanford, Calif., said the RUTH study "highlights the need to consider the risk of breast cancer as well as other risks and coexisting conditions in determining whether and when [Evista] or another SERM is warranted for an individual woman." "For women represented by the RUTH cohort of women with or at increased risk for CHD, the moderate benefits of raloxifene for breast cancer prophylaxis do not seem to justify the risks" she wrote. "For now," Dr. Stefanick continued, "there is no magic bullet that can reduce the risks of major health problems related to estrogens and aging without introducing other potentially serious health concerns."

Frequent Estradiol misspellings: wstradiol, sstradiol, dstradiol, rstradiol, 4stradiol, 3stradiol, eatradiol, eztradiol, extradiol, edtradiol, eetradiol, ewtradiol, esrradiol, esfradiol, esgradiol, esyradiol, es6radiol, es5radiol, esteadiol, estdadiol, estfadiol, esttadiol, est5adiol, est4adiol, estrzdiol, estrsdiol, estrwdiol, estrqdiol, estrasiol, estraxiol, estraciol, estrafiol, estrariol, estraeiol, estraduol, estradjol, estradkol, estradool, estrad9ol, estrad8ol, estradiil, estradikl, estradill, estradipl, estradi0l, estradi9l, estradiok, estradiop, estradioo, stradiol, etradiol, esradiol, estadiol, estrdiol, estraiol, estradol, estradil, estradio, setradiol, etsradiol, esrtadiol, estardiol, estrdaiol, estraidol, estradoil, estradilo, eestradiol, esstradiol, esttradiol, estrradiol, estraadiol, estraddiol, estradiiol, estradiool, estradioll

Estradiol search phrases: Estradiol uses, Estradiol mail order, Estradiol medicine, Estradiol pharmacy, Estradiol pill, Estradiol drugs, Estradiol stories, Estradiol without prescription, Estradiol generic, Estradiol without rx, Estradiol prescription